Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Drug Category : Array
Conference Category : Array
Lead Author : Lunning M, O'Brien S, et al.
Published Date : 02/06/2015
Download Link : https://www.tgtherapeutics.com/ASCO%20Doublet%20Poster%20FINAL.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top